Immuron (NASDAQ:IMRN) Stock Falls 2.2% – Time to Sell?

Immuron (NASDAQ:IMRN) fell 2.2% on Friday. The stock traded as low as $0.78 and last traded at $0.8312. Approximately 11,605 shares traded hands during trading, a decline of 58% from the average session volume of 27,810 shares. The stock had previously closed at $0.8499.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Immuron in a report on Monday, September 21st. One research analyst has rated the stock with a Sell rating. According to MarketBeat, Immuron currently has a consensus rating of “Sell”.

Immuron Price Performance

The stock’s 50-day moving average price is $1.13 and its 200 day moving average price is $1.01.

Immuron (NASDAQ:IMRN) last announced its earnings results on Friday, August 14th. The company reported ($0.08) earnings per share for the quarter. The company had revenue of $1.27 million during the quarter.

About Immuron

Immuron Limited is a biopharmaceutical company focused on developing and commercializing orally delivered antibody-based therapies for gastrointestinal and immune-related conditions. The company’s technology uses hyperimmune bovine colostrum to produce antibodies designed to bind targeted pathogens or disease-associated molecules in the gastrointestinal tract.

Immuron’s primary commercial product is Travelan, an oral immunotherapy intended to help prevent travelers’ diarrhea caused by enterotoxigenic Escherichia coli (ETEC).